Eluvia Meta-Analysis
The Eluvia Meta-Analysis is a systematic review and meta-analysis of proportions comparing the performance of Eluvia DES, Zilver PTX, Viabahn and Bare Metal Stents (BMS) at 12 and 24 months. Eluvia DES demonstrated consistently greater primary patency and TLR outcomes at 12 and 24 months compared to all other stent types, with no difference in mortality rates.
Paclitaxel Devices for Femoropopliteal Disease Presented at Charing Cross 2025
Prof. Andrew Holden, Prof. Gunnar Tepe, and Prof. Giovanni Torsello describe the performance of stenting in femoropopliteal disease.
In the meta-analysis, Eluvia delivers consistently stronger primary patency and TLR outcomes compared to all other stent types
Primary Patency
Target Lesion Revascularization
Eluvia DES is the definitive treatment choice for long, complex lesions.
Additionally, in contrast to comparative stents, Eluvia DES primary patency rates remained stronger compared with all other stent types and did not decline in long lesions (>150mm) at 12 and 24 months.
12-Month Primary Patency
Short & Long Lesions
24-Month Primary Patency
Short & Long Lesions
References:
Holden, A. Performance of Stenting in Femoropopliteal Disease: Systematic Literature Review and Meta-analysis of Proportions. Presented at Charing Cross 2025.